Trial Profile

A open-label, phase 2, feasibility trial investigator-initiated-trial (IIT) to investigate safety, tolerability, and acceptability of administering 2 daily doses of 40 mg of pomaglumetad methionil for first-episode psychosis (FEP) or clinical high risk (CHR) of psychosis

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2026 According to a Denovo Biopharma media release, today announced a partnership with Orygen to initiate a Phase 2 investigator-initiated-trial (IIT) to study DB103 (pomaglumetad methionil) for first-episode psychosis (FEP) or clinical high risk (CHR) of psychosis.
19 Feb 2026 According to a Denovo Biopharma media release, study is being led by Professor Patrick McGorry, M.D., and sponsored by Orygen in Parkville, Australia.
19 Feb 2026 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com